Emergent Biosolutions financials
$6.92+0.87%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $742.9M | $1.04B | $1.05B | $1.12B | $1.77B | $1.58B | $1.11B | $782.4M | $560.9M | $488.8M |
| Gross profit | $416.7M | $362.3M | $343.9M | $424.4M | $1.03B | $1.04B | $672.5M | $460.1M | $373.2M | $362.5M |
| Gross margin | 56.1% | 34.7% | 32.8% | 38.0% | 57.8% | 66.0% | 60.8% | 58.8% | 66.5% | 74.2% |
| Operating income | $100.1M | -$108.7M | -$726.4M | -$170.0M | $341.4M | $438.5M | $114.1M | $89.8M | $124.3M | $105.5M |
| Net income | $52.6M | -$190.6M | -$760.5M | -$211.6M | $219.5M | $305.8M | $54.5M | $62.7M | $82.6M | $55.9M |
| Net margin | 7.1% | −18.3% | −72.5% | −18.9% | 12.4% | 19.4% | 4.9% | 8.0% | 14.7% | 11.4% |
| Diluted EPS | $0.93 | $-3.60 | $-14.85 | $-4.22 | $4.06 | $5.68 | $1.04 | $1.22 | $1.71 | $1.13 |
| EBITDA | $208.1M | $27.3M | -$76.4M | -$20.0M | $506.9M | $553.0M | $224.8M | $152.0M | $166.9M | $143.7M |
| Operating cash flow | $170.6M | $58.7M | -$206.3M | -$34.1M | $320.2M | $505.2M | $163.2M | $38.7M | $208.1M | $54.6M |
| Free cash flow | $156.8M | $35.8M | -$257.9M | -$393.6M | $96.1M | $363.3M | $76.3M | -$33.4M | $75.7M | -$21.6M |
| Diluted shares | 56.7M | 53.0M | 51.2M | 50.1M | 54.1M | 53.8M | 52.4M | 51.4M | 50.3M | 49.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $205.4M | $99.5M | $111.7M | $642.6M | $576.1M | $621.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $572.1M | $663.7M | $860.2M | $1.41B | $841.0M | $874.8M |
| Total assets | $1.32B | $1.39B | $1.82B | $3.17B | $2.96B | $2.88B |
| Total liabilities | $796.0M | $906.9M | $1.17B | $1.78B | $1.35B | $1.44B |
| Shareholders' equity | $522.6M | $482.8M | $649.3M | $1.39B | $1.61B | $1.45B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology